Phase 2 COPD Trial, Recruiting NCT06110403 Sponsor: University Hospital, Lille Condition: COPD
Back to Copd

Phase 2 COPD Trial, Recruiting

NCT06110403
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 40 to 75 years old at the time of joining the trial
  • People who have a confirmed diagnosis of COPD, with breathing test results showing a specific level of airflow limitation and reduced lung function (confirm with trial site for exact test values)
  • People with a smoking history of more than 10 "pack-years" — a measure that combines how much and how long a person has smoked (confirm with trial site)
  • People who experience significant breathlessness in daily life, rated at level 2 or higher on a standard breathlessness scale
  • People who are willing and able to sign a consent form before any study procedures begin

Who may not be able to join:

  • People who have been diagnosed with asthma, or a condition where asthma and COPD overlap
  • People who have had a chest infection or a COPD flare-up within the past 6 weeks, or within 2 months if it required a hospital stay
  • People who have had serious heart problems in the past 6 months, such as a heart attack, unstable chest pain, or certain heart procedures
  • People with moderate to severe heart failure, significant structural heart conditions, or certain irregular heart rhythms
  • People with certain heart electrical problems detected on a heart tracing (ECG), unless they have a pacemaker (confirm with trial site)
  • People with a resting heart rate below 45 beats per minute
  • People with uncontrolled high blood pressure (above 165/95 mmHg)
  • People with significant lung or breathing conditions other than COPD
  • People with severely reduced kidney function
  • People with liver problems
  • People with a type of eye condition called narrow-angle glaucoma that has not been adequately treated
  • People with significant urinary problems related to prostate enlargement or bladder issues
  • People who are unable to complete the required breathing tests involved in the study
  • People who have a medical reason why they cannot use the types of inhaled medications being studied
  • People who are pregnant or breastfeeding
  • Women who are able to become pregnant and are not using effective contraception
  • People who have been diagnosed with any type of cancer within the past 5 years
  • People who are under legal guardianship
  • People who are unable or unwilling to provide consent
  • People who do not have social insurance coverage

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Thierry PEREZ, MD, University Hospital, Lille

Phone: 0320445962

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
29 September 2023
Est. completion
1 September 2026

Where this trial is recruiting

🇫🇷 France

Primary endpoints

change in ventilation pattern complexity and variability

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov